The biochemistry of Tourette's Syndrome

Metabolic Brain Disease

Volumn 10, Issue 2, 1995, Pages 107-124

  Chokka, P R ^a   Baker, G B ^a   Bornstein, R A ^b   de Groot, C M ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; ACETYLCHOLINE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANDROGEN; CATECHOLAMINE; CLONAZEPAM; CLONIDINE; CYCLIC AMP; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; FLUTAMIDE; GLUTAMIC ACID; HALOPERIDOL; INDOLEACETIC ACID; KYNURENINE; NORADRENALIN; NORMETADRENALIN; OPIATE PEPTIDE; PHENETHYLAMINE; PHENYLALANINE; PIMOZIDE; SEROTONIN; TRYPTAMINE; TRYPTOPHAN; TYROSINE; UNINDEXED DRUG;

AUTOSOMAL DOMINANT INHERITANCE; CHOLINERGIC SYSTEM; CLINICAL TRIAL; DOPAMINERGIC SYSTEM; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MINIMAL BRAIN DYSFUNCTION; NONHUMAN; OBSESSION; REVIEW; SECOND MESSENGER; SEROTONINERGIC SYSTEM;

AMINO ACID NEUROTRANSMITTERS; BIOGENIC AMINE NEUROTRANSMITTERS; HUMAN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TOURETTE SYNDROME;

EID: 0029039204     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/BF01991859     Document Type: Review

References (153)

1. Parallel organization of functionally segregated circuits linking basal ganglia and cortex
2. Postmortem analysis of subcortical monoamines and amino acids in Tourette syndrome
3. Reduced excretion of MHPG in Tourette's syndrome
4. Urinary excretion of metabolites of norepinephrine in Tourette's syndrome
5. Phenylethylaminergic mechanisms in attention deficit disorder
6. Trace amines and Tourette's syndrome
7. A family study of obsessive-compulsive disorder
8. Tourette's syndrome: two views
9. Phenylethylamine metabolism in Tourette's syndrome
10. Urinary amines in Tourette's syndrome patients with and without phenylethylamine abnormality
11. Neuropsychological performance and urinary phenylethylamine in Tourette's syndrome
12. Urinary indoleamines in Tourette Syndrome patients with obsessive-compulsive characteristics
13. Urinary amines in adults with Tourette's syndrome
14. Trace amines and the neurosciences: an overview
15. Role of γ-aminobutyric acid in antipanic drug efficacy
16. PET studies on the integrity of the pre and postsynaptic dopaminergic system in Tourette syndrome
17. The natural history of Tourette Syndrome
18. Gilles de la Tourette's syndrome: an overview of clinical experience
19. Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder
20. Prevalence of Gilles de la Tourette's syndrome in North Dakota adults
21. Biogenic amine metabolism in Tourette syndrome
22. Computed tomographic brain scanning in children with developmental neuropsychiatric disorders
23. Commentary on sequential use of opioid antagonists and agonists in Tourette's syndrome
24. Neuroendocrine and behavioral effects of naloxone in Tourette syndrome
25. Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's Syndrome: a pilot study
26. Enhanced stress responsivity of Tourette Syndrome patients underoing lumbar puncture
27. Comorbidity, Tourette syndrome, and anxiety disorders
28. Chronic multiple tics of Gilles de la Tourette's disease. CSF acid monoamine metabolites after probenecid administration
29. Central biogenic amine metabolism in children with the syndrome of chronic multiple tics of Gilles de la Tourette
30. Alternative hypotheses on the inheritance of Tourette syndrome
31. An epidemiological study of Tourette's syndrome in a single school district
32. Association between Tourette's syndrome and homozygosity at the dopamine D3 receptor gene
33. Authors' reply
34. Biogenic amines and their metabolites in body fluids of normal, psychiatric, and neurological subjects
35. Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry
36. Fluvoxamine/pimozide treatment of concurrent Tourette's and obsessive-compulisve disorder
37. Structural imagining in Tourette Syndrome
38. Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions
39. Tourette's syndrome and nicotine withdrawal
40. Excitatory amino acid transmitters
41. Tourette's syndrome: current approaches to recognition and management
42. Evidence that 5-HT2 receptor activation decreases noradrenaline release in rat hippocampus in vivo
43. Studies on the mechanisms of action of β-phenylethylamine stereotypy in rodents: implications for a β-phenylethylamine animal model of schizophrenia
44. Elevated plasma kynurenine in Tourette syndrome
45. Complex of rapid movements and vocalization induced by RX336-M in mice: possible relevance to Tourette's syndrome
46. The serontonin/norepinephrine link beyond the β-adrenoceptor
47. Drug treatment for hyperactive children. Therapeutic guidelines
48. Gilles de la Tourette's syndrome
49. Obsessions and compulsions in Gilles de la Tourette's syndrome
50. Glutamatergic mechanisms mediating stimulant and antipsychotic drug effects
51. Phenylethylamine deamination in the noradrenergic neurotransmitter system
52. Exclusion of close linkage of Tourette's syndrome to D1-dopamine receptor
53. D2 dopamine receptor alleles do not influence severity of Tourette's syndrome — results from four large kindreds
54. Elevated frontal cerebral blood flow in Gilles de la Tourette Syndrome — A Tc-99 (m)-MHPAO SPECT study
55. Fluvoxamine and sulpiride in comorbid obsessive-compulsive disorder and Gilles de la Tourette syndrome
56. Sleep in Gilles de la Tourette's syndrome: disorder of arousal
57. Clonidine and clonazepam in Tourette Syndrome
58. The relationship between stimulant medication and tics
59. Gilles de la Tourette's syndrome: a postmortem neuropathological and immunohistochemical study
60. Basal ganglia peptidergic staining in Tourette syndrome: a follow-up study
61. Serotonin and Tourette's syndrome: movements such as head-shakes and wet-dog shakes may model human tics
62. Tourette's syndrome and homozygosity for the dopamine D3 receptor gene
63. Possible involvement of dopamine in the long-term serotonin depletion by p-chloroamphetamine and ß,ß-difluoro-p-chloroamphetamine in rats
64. The use of benzodiazepines in obsessive compulsive disorder and Tourette's syndrome
65. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia
66. Deprenyl in attention deficit associated with Tourette's syndrome
67. Electrophysiological studies of the possible role of trace amines in synaptic function
68. The effects of some antipsychotic drugs, D-amphetamine and reserpine on the concentration and rate of accumulation of tryptamine and 5-hydroxytryptamine in the mouse striatum
69. Tryptamine depletion in the rat striatum following electrolytic lesions of the substantia nigra
70. Tryptamine may couple dopaminergic and serotonergic transmission in the brain
71. Epidemiology and comorbidity. The North Dakota prevalence studies of Tourette syndrome and other developmental disorders
72. Gilles de la Tourette syndrome after long-term chlorpromazine therapy
73. Tourette's syndrome and attention deficit hyperactivity disorder: evidence for a genetic relationship
74. Cerebrospinal fluid monoamine metabolites in Tourette syndrome and their neuroendocrine implications
75. Severity of Tourette's syndrome in one large kindred: implications for determination of disease prevalence rate
76. A controlled trial of propoxyphene and naltrexone in patients with Tourette's syndrome
77. Catecholamine metabolism in Gilles de la Tourette's syndrome
78. Involvement of newly synthesized catcholamines in the modulation by trace amines of the release of neurotransmitters
79. Acute and chronic clonidine treatment in Tourette's syndrome: a preliminary report on clinical response and effect on plasma and urinary catecholamine metabolites, growth hormone and blood pressure
80. Clonidine treatment of Gilles de la Tourette's Syndrome
81. Elevated CSF dynorphan A[1-8] in Tourette's syndrome
82. Possible exacerbation of tics by androgenic steroids (letter)
83. Tics and Tourette's disorder: a 2- to 7-year follow-up of 54 obsessive-compulsive children
84. Therapeutics of Tourette Syndrome: new medication approaches
85. Regulation of the concentration of dynorphin A1-8 in the striatonigral pathway by the dopaminergic system
86. Opiate withdrawal unmasks Tourette's syndrome
87. Stimulant medications precipitate Tourette's Syndrome
88. The serotonin/noradrenaline-link in brain. I. The role of noradrenaline and serotonin in the regulation of density and function of β-adrenoceptors and its alteration by desipramine
89. G proteins: implications for psychiatry
90. Coprolalia associated with hemiballismus: response to tetrabenazine
91. Tryptamine turnover: effects of drugs
92. Sequential use of opioid antagonists and agonists in Tourette's syndrome
93. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder
94. Amino acid neurotransmitters
95. Psychopharmacology in children with developmental disabilities
96. Blood choline and response to clonazepam and haloperidol in Tourette's syndrome
97. Methadone treatment of Tourette's disorder (letter)
98. Multiple tic syndrome (Gilles de la Tourette's syndrome)
99. Tryptamine: a metabolite of tryptophan implicated in various psychiatric disorders
100. Blunted growth hormone response to clonidine in Gilles de la Tourette Syndrome
101. G proteins and cyclic nucleotides in the nervous system
102. Association analysis of the dopamine D2 receptor gene in Tourette's syndrome using the haplotype relative risk method
103. Electrophysiological, biochemical and behavioural evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function
104. 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system?
105. Tourette syndrome and attention deficit disorder: evidence against a genetic relationship
106. Familial relationship between Gilles de la Tourette's syndrome, attention deficit disorder, learning disabilities, speech disorders, and stuttering
107. Gilles de la Tourette's syndrome and obsessive compulsive disorder: evidence supporting a genetic relationship
108. Corpus callosum morphology from magnetic resonance images in Tourette's syndrome
109. Steroid hormones and Tourette's syndrome — early experience with antiandrogen therapy
110. Reduced basal ganglia volumes in Tourette's syndrome using 3-dimensional reconstruction techniques from magenetic resonance images
111. Low plasma GABA is a trait-like marker for bipolar illness
112. A twin study of Tourette's syndrome
113. Possible interactions between dynorphin and dopaminergic systems in rat basal ganglia and substantia nigra
114. Decreased3H-quinuclidinyl benzilate binding to lymphocytes in Gilles de la Tourette Syndrome
115. Clinical features and long-term treatment with pimozide in 65 patients with Gilles de la Tourette's syndrome
116. Pharmacological treatment of Gilles de la Tourette's syndrome
117. Microstructureal analysis of the symptoms of Tourette's syndrome and the effects of a trial use of a transdermal nicotine patch
118. The Gilles de la Tourette Syndrome: the current status
119. The psychopathology of Gilles de la Tourette syndrome: a phenomenological analysis
120. Neurochemistry and child and adolescent psychiatry
121. NMDA-GABA interactions in an animal model of behaviour: a gating mechanism from motivation toward psychotic-like symptoms
122. Invited review — Gilles de la Tourette Syndrome: a neuropsychiatric disorder
123. The effects of naloxone in Tourette's syndrome
124. Tourette's Syndrome, Part I: Definition and Diagnosis and Tourette's Syndrome, Part II: Contemporary approaches to assessment and treatment
125. Hemiballismus (review)
126. Enzyme activity in Tourette's syndrome
127. Treatment of tics and Tourette syndrome
128. Effect of chronic haloperidol on the levels of blood and urinary phenylethylamine and phenylacetic acid in rats
129. Transdermal nicotine patch and potentiation of haloperidol in Tourette's syndrome
130. Neurochemical analysis of postmortem cortical and striatal brain tissue in patients with Tourette syndrome
131. Tourette syndrome: a neurochemical analysis of postmortem cortical brain tissue
132. Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette syndrome
133. CSF cholinesterase activity in Gilles de la Tourette's syndrome
134. Volumetric MRI changes in basal ganglia of children with Tourette's syndrome
135. The development of behavioural and emotional problems in Tourette syndrome
136. Clinical symptomatology, CSF neurotransmitter metabolites, and serum haloperidol levels in Tourette Syndrome
137. Tourette syndrome and other tic disorders. Diagnosis, pathophysiology, and treatment
138. Positron emission tomography evaluation of dopamine D2 receptors in adults with Tourette Syndrome
139. Effects of RS-86, an orally active cholinergic agonist, on sleep in man
140. Physostigmine in Tourette syndrome: evidence for cholinergic underactivity
141. Functional neuroanatomy of Tourette syndrome. Limbic-motor interactions studies with FDG PET
142. Gilles de la Tourette Syndrome
143. Noradrenergic and dopaminergic mechanisms in Gilles de la Tourette's syndrome
144. PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome
145. Excitatory amino acid receptors in schizophrenia
146. The genetics of the Gilles de la Tourette syndrome — a review
147. Tourette's syndrome and the opioid system
148. D2 dopamine receptors are elevated in neuropsychiatric disorders other than schizophrenia
149. Phenylethylamine excretion in attention deficit disorder